POINT Biopharma Global Inc.

Activity by year

2023202420252026

AcquisitionContract

Oct 3, 2023ACQUISITIONIndianapolis, Indiana, United States
Eli Lilly to acquire POINT Biopharma for radioligand therapies
Eli Lilly and Company announced a definitive agreement to acquire POINT Biopharma, a radiopharmaceutical company with a pipeline of radioligand therapies for cancer. The acquisition includes POINT's manufacturing campus in Indianapolis and R&D center in Toronto.
Eli Lilly and Company acquirer POINT Biopharma Global Inc. target #Medical Devices investor.lilly.com
Jul 31, 2023CONTRACT
ITM and POINT Biopharma expand supply agreement for lutetium-177
ITM Isotope Technologies Munich SE and POINT Biopharma Global Inc. expanded their global supply agreements for non-carrier-added lutetium-177 (n.c.a. 177Lu) to support POINT's clinical and commercial development. Financial details were not disclosed.
ITM Isotope Technologies Munich SE supplier POINT Biopharma Global Inc. customer itm-radiopharma.com

Suppliers

Acquired by

Loading…